Biotech Values

[genisi]

They have seemed to be one of the few (small) oncology companies that has had consistent successes and monocolonals seem to (still) be a promising technology

Not all went well, SGN-33 development was discontinued recently and one of the SGN-40 trials was discontinued (phase IIb in DLBCL). One note is that the former two are unconjugated monoclonal antibodies, while SGN-35 is an antibody-drug conjugate.

I'm guessing they want to move to front-line and other indications

Quite so, see this phase I trial - Treatment-naive Hodgkin lymphoma so yes, they want to move to front line:

http://clinicaltrials.gov/ct2/show/NCT01060904?term=SGN-35&rank=10

And other indications - already in phase II in Anaplastic Large Cell Lymphoma (ALCL):

http://clinicaltrials.gov/ct2/show/NCT00866047?term=sgn-35+ALCL&rank=1